Nathan N Morgan

发表

Design, synthesis and structure-activity relationships of azole acids as novel, potent dual PPAR alpha/gamma agonists.

Wei Wang, Jonathan Lippy, Arthur M Doweyko, 2009, Bioorganic & medicinal chemistry letters.

Synthesis and biological evaluation of novel pyrrolidine acid analogs as potent dual PPARα/γ agonists.

Weiqi Wang, A. Doweyko, T. Harrity, 2015, Bioorganic & medicinal chemistry letters.

Aglycone exploration of C-arylglucoside inhibitors of renal sodium-dependent glucose transporter SGLT2.

W. Humphreys, T. Waldron, Songping Han, 2008, Bioorganic & medicinal chemistry letters.

Discovery of 3-hydroxy-4-cyano-isoquinolines as novel, potent, and selective inhibitors of human 11β-hydroxydehydrogenase 1 (11β-HSD1).

S. Sheriff, R. Seethala, A. Nayeem, 2011, Bioorganic & medicinal chemistry letters.

7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.

Wei Wang, C. Weigelt, K. Kish, 2011, Bioorganic & medicinal chemistry letters.

Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).

C. Weigelt, K. Kish, H. Klei, 2013, Journal of medicinal chemistry.

Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.

W. Humphreys, O. Flint, E. Janovitz, 2008, Journal of medicinal chemistry.

Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists.

A. Doweyko, T. Harrity, Litao Zhang, 2008, Bioorganic & medicinal chemistry letters.

Discovery of Clinical Candidate 2-((2S,6S)-2-Phenyl-6-hydroxyadamantan-2-yl)-1-(3'-hydroxyazetidin-1-yl)ethanone [BMS-816336], an Orally Active Novel Selective 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor.

David K. Leahy, J. Barrish, M. Kirby, 2017, Journal of medicinal chemistry.

Optimization of 1,2,4-Triazolopyridines as Inhibitors of Human 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD-1).

S. Sheriff, R. Seethala, A. Nayeem, 2014, ACS Medicinal Chemistry Letters.

Discovery of Clinical Candidate BMS-823778 as an Inhibitor of Human 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD-1).

S. Sheriff, R. Seethala, A. Nayeem, 2018, ACS medicinal chemistry letters.